PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
PharmAbcine Inc. announced that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
November 17, 2020
by prnasia
PharmAbcine Partners with Samsung Biologics for PMC-403
The antibody is expected to enter a global ophthalmological clinical trial in 2022.
September 22, 2020
by contractpharma
PharmAbcine Signs CMO Contract with Binex
CDMO Binex to produce olinvacimab at its new 5,000L production line.
September 17, 2020
by contractpharma
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior b
August 4, 2020
by prnasia
PharmAbcine, SLBio Enter NSCLC Research Pact
To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.
August 4, 2020
by contractpharma
PharmAbcine Enters Partnership with Thermo Fisher
Will develop and manufacture Thermo Fisher’s immune checkpoint blockade, PMC-309 for Phase I.
June 16, 2020
by contractpharma
Samsung Biologics, PharmAbcine Enter Antibody Pact
To develop and manufacture PMC-402, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders.
April 7, 2020
by contractpharma